This week, 4 Biotechnology stocks are improving their overall rating on Portfolio Grader. Each of these rates an “A” (“strong buy”) or “B” overall (“buy”).

Eagle Pharmaceuticals, Inc.’s (EGRX) ratings are looking better this week, moving up to a B from last week’s C. The company also gets A’s in sales growth and earnings revisions. For more information, get Portfolio Grader’s complete analysis of EGRX stock.

This week, Summit Therapeutics PLC Sponsored ADR’s (SMMT) ratings are up from a C last week to a B. For more information, get Portfolio Grader’s complete analysis of SMMT stock.

Argos Therapeutics, Inc. (ARGS) is seeing ratings go up from a C last week to a B this week. Argos Therapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases based on its proprietary technology platform. The company also gets A’s in sales growth and earnings momentum. For more information, get Portfolio Grader’s complete analysis of ARGS stock.

The rating of Macrocure Ltd. (MCUR) moves up this week, rising from a C to a B. For more information, get Portfolio Grader’s complete analysis of MCUR stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.